Diffuse Large B-cell Lymphoma
📧 Sign up to get email alerts when something new happens for Diffuse Large B-cell Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-02-04Clinical Trial Update: Evaluation of Bridging Radiation Therapy Before CAR T-Cell Infusion for the Treatment of Relapsed or Refractory Large B-Cell Lymphoma [EARLY_Phase 1]
This clinical trial update notes a Phase 1 study evaluating bridging radiation therapy before CAR T-cell infusion for relapsed or refractory…
-
CLINICAL_TRIALS research · 2026-02-04Clinical Trial Update: Glofitamab as a Bridge to and/or Consolidation Post Autologous Stem Cell Transplant in Patients With Relapsed B Cell Lymphomas [Phase 2]
Phase 2 clinical trial evaluating glofitamab as a bridge to and/or consolidation after autologous stem cell transplant in patients with rela…
-
CLINICAL_TRIALS research · 2026-02-04Clinical Trial Update: Mosunetuzumab and Polatuzumab Vedotin With Split-Dose CHP Chemotherapy for Elderly Patients With Diffuse Large B-Cell Lymphoma [Phase 2]
This is a Phase 2 trial evaluating a combination of mosunetuzumab and polatuzumab vedotin with split-dose CHP chemotherapy in elderly patien…
-
CLINICAL_TRIALS research · 2026-02-02Clinical Trial Update: Phase I Master Protocol of Novel Combination Therapy for Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma [EARLY_Phase 1]
Phase I master protocol trial evaluating a novel combination therapy for patients with relapsed or refractory aggressive B-cell lymphomas.
-
CLINICAL_TRIALS research · 2026-02-02Clinical Trial Update: Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma [Phase 2]
A Phase 2 clinical trial update describes testing additional drug treatments after CAR T-cell therapy in patients with relapsed or refractor…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2026-01-30Clinical Trial Update: Clinical Trial of TQB2825 Injection Combined Immunochemotherapy in Subjects With Diffuse Large B Cell Lymphoma [Phase 1, Phase 2]
A phase 1/2 clinical trial of TQB2825 injection combined with immunochemotherapy for Diffuse Large B Cell Lymphoma is currently recruiting.
-
CLINICAL_TRIALS research · 2026-01-29Clinical Trial Update: Optimizing Cellular and Humoral Immunity by Vaccinating With PCV13 Before and After CAR-T Therapy [Phase 2]
A Phase 2 trial is evaluating whether vaccination with Prevnar 13 before and after CAR-T therapy can enhance cellular and humoral immunity i…
-
CLINICAL_TRIALS research · 2026-01-28Clinical Trial Update: Application of Zanubrutinib-based Combination Regimens in the Treatment of Newly-diagnosed Diffuse Large B-cell Lymphoma [Phase 2]
Phase 2 clinical trial evaluating zanubrutinib-based combination regimens for newly diagnosed diffuse large B-cell lymphoma; currently recru…
-
CLINICAL_TRIALS research · 2026-01-28Clinical Trial Update: Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell Therapy [Phase 2]
A Phase 2 clinical trial investigates golcadomide in combination with rituximab as bridging therapy for relapsed or refractory aggressive B-…
-
CLINICAL_TRIALS research · 2026-01-28Clinical Trial Update: Safety and Efficacy Study of Anti-PD1 Armored CD19 CAR-T Cells in Adult Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma [Phase 1]
A Phase 1 safety and efficacy study of anti-PD1 armored CD19 CAR-T cells in adults with relapsed or refractory diffuse large B-cell lymphoma…
-
CLINICAL_TRIALS research · 2026-01-28Clinical Trial Update: Registry Platform Hematologic Malignancies (RUBIN) - Extension of Tumor Registry Lymphatic Neoplasms
Clinical trial registry update for the RUBIN platform extension focusing on hematologic malignancies. It is currently recruiting for conditi…
-
CLINICAL_TRIALS research · 2026-01-28Clinical Trial Update: Digital Health Intervention for Self-Management and Telemonitoring in Chimeric Antigen Receptor (CAR-T) Therapy [Phase 3]
Phase 3 clinical trial evaluating a digital health intervention for self-management and telemonitoring in CAR-T therapy is currently recruit…
-
CLINICAL_TRIALS research · 2026-01-28Clinical Trial Update: Quality Of Life and Drug Use in Patients With CAR-T Cells
Clinical trial update focused on quality of life and drug use in patients treated with CAR-T cells for diffuse large B-cell lymphoma. The st…
-
CLINICAL_TRIALS research · 2026-01-23Clinical Trial Update: ctDNA-guided Therapy Optimization in Newly Diagnosed DLBCL [NA]
This clinical trial update describes a study evaluating ctDNA-guided therapy optimization for newly diagnosed diffuse large B-cell lymphoma,…
-
CLINICAL_TRIALS research · 2026-01-23Clinical Trial Update: Zanubrutinib in Patients With DLBCL and MYD88 or NOTCH1 Mutation or CD5+ [Phase 2]
This clinical trial update reports a Phase 2 study evaluating zanubrutinib in patients with diffuse large B-cell lymphoma who have MYD88 or …
-
CLINICAL_TRIALS research · 2026-01-22Clinical Trial Update: Investigator Initiated Study to Assess the Safety of Combination of CLS-015 With Anti-CD-19 CAR-T Cells in Patients With Stable/Progressive Large B Cell Lymphoma at Lymphodepletion. [Phase 1]
Investigator-initiated Phase 1 study to evaluate the safety of combining CLS-015 with anti-CD-19 CAR-T cells in patients with diffuse large …
-
CLINICAL_TRIALS research · 2026-01-21Clinical Trial Update: Relmacabtagene Autoleucel Combined With Sintilimab for Relapsed/Refractory B-cell Lymphoma [Phase 2]
Phase 2 clinical trial update evaluating Relmacabtagene autoleucel in combination with sintilimab for relapsed/refractory B-cell lymphomas; …
-
CLINICAL_TRIALS research · 2026-01-20Clinical Trial Update: Communication Skills Intervention to Promote Transition Into Survivorship
This clinical trial update describes a communication skills intervention intended to help patients with Hodgkin lymphoma and diffuse large B…
-
CLINICAL_TRIALS research · 2026-01-16Clinical Trial Update: A Multicenter, Prospective, Randomized, Controlled Study of Decitabine in Combination With R-CHOP for Initial Treatment of EBV+ Diffuse Large B-cell Lymphoma [Phase 3]
A multicenter, prospective phase 3 randomized study evaluating decitabine added to R-CHOP as initial therapy for EBV-positive diffuse large …
-
CLINICAL_TRIALS research · 2026-01-16Clinical Trial Update: A Study to Assess the Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), or Chronic Lymphocytic Leukemia (CLL) [Phase 1]
Phase 1 clinical trial update for ABBV-319 evaluating adverse events, change in disease activity, and pharmacokinetics in adults with relaps…
-
CLINICAL_TRIALS research · 2026-01-15Clinical Trial Update: An Open and Dose-escalation Early Clinical Study of CD19 and CD20 CAR-T Cell Therapy for Relapsed or Refractory Aggressive B-cell Lymphoma [EARLY_Phase 1]
An open, dose-escalation early Phase 1 study of CAR-T cells targeting CD19 and CD20 for relapsed or refractory aggressive B-cell lymphoma is…
-
CLINICAL_TRIALS research · 2026-01-14Clinical Trial Update: ST-067 in Combination With CD19-Directed CAR T-Cell Therapy (Liso-cel) in Relapsed/Refractory Large B-Cell Lymphoma [Phase 1, Phase 2]
Ongoing Phase 1/2 study evaluating ST-067 in combination with CD19-directed CAR T-cell therapy (Liso-cel) for relapsed/refractory diffuse la…
-
CLINICAL_TRIALS research · 2026-01-14Clinical Trial Update: Glofitamab in Real Life
A real-world clinical trial of glofitamab for diffuse large B-cell lymphoma is currently recruiting.
-
CLINICAL_TRIALS research · 2026-01-14Clinical Trial Update: Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma [Phase 1]
This is a Phase 1 trial evaluating anti-CD19 CAR-T cell therapy for relapsed or refractory non-Hodgkin lymphoma. The study is currently recr…
-
CLINICAL_TRIALS research · 2026-01-14Clinical Trial Update: A Study of Axicabtagene Ciloleucel and Glofitamab as Second-Line Therapy for Relapsed or Refractory Patients With Large B Cell Lymphoma [Phase 2]
A Phase 2 clinical trial is evaluating the combination of axicabtagene ciloleucel and glofitamab as second-line therapy for relapsed or refr…